<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374516</url>
  </required_header>
  <id_info>
    <org_study_id>CYD15</org_study_id>
    <secondary_id>UTN: U1111-1116-4986</secondary_id>
    <nct_id>NCT01374516</nct_id>
  </id_info>
  <brief_title>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America</brief_title>
  <official_title>Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in
      preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin
      America.

      Primary Objective:

      To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in
      preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the
      severity, due to any of the four serotypes in children and adolescents aged 9 to 16 years at
      the time of inclusion.

      Secondary Objectives:

        -  To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after
           the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.

        -  To describe the occurrence of hospitalized VCD cases and the occurrence of severe
           (clinically severe or as per World Health Organization (WHO) criteria) VCD cases,
           throughout the Surveillance Expansion Period (SEP) and throughout the trial (from Day 0
           until the end of the study).

        -  To describe the antibody response to each dengue serotype after Dose 2, after Dose 3,
           and 1 and 5 years after Dose 3.

        -  To describe the occurrence of serious adverse events (SAEs), including SAEs of special
           interest in all participants throughout the trial period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were randomized to either receive 3 injections of CYD dengue vaccine or a
      placebo at 0, 6, and 12 months.

      A subset of participants from each country (N=2000) was also evaluated for reactogenicity and
      immunogenicity.

      For each participant, the Active Phase of dengue case detection began after the first
      injection (Dose 1) and continued until 13 months after the third injection (Dose 3). It was
      assumed that 12 months of surveillance should result in the detection of a sufficient number
      of VCD cases to allow for an assessment of efficacy.

      The Hospital Phase began after the Active Phase. Participants with a febrile illness and
      requiring hospitalization were screened for dengue until the end of the study.

      Participants who consented to participate in the SEP were actively followed for dengue case
      detection (i.e. at least weekly contact and capturing any acute febrile illness, not just
      hospitalized febrile cases, as in the Active Phase). The SEP was designed to maximize the
      detection of symptomatic VCD (hospitalized or not) in order to describe CYD dengue vaccine
      efficacy and safety in preventing symptomatic dengue in the long-term. Participants who
      declined participating in the SEP continued surveillance as in the Hospital Phase until trial
      completion.

      Symptomatic VCD cases occurring more than (&gt;) 28 days after dose 3 (during the Active Phase)
      are defined as:

        -  Acute febrile illness (i.e. temperature &gt;=38 degree Celsius (°C) on at least 2
           consecutive days)

        -  Virologically confirmed by dengue Reverse Transcriptase-Polymerase Chain Reaction
           (RT-PCR) and/or dengue non-structural (NS)1 enzyme-linked immunosorbent assay (ELISA) Ag
           test.

      Severity was assessed using a definition consistent with the 1997 WHO Classification Dengue
      Hemorrhagic Fever and by an independent Data Monitoring Committee (IDMC) severity criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2011</start_date>
  <completion_date type="Actual">March 5, 2018</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction (RT-PCR) and/or dengue non-structural (NS) protein 1 antigen enzyme-linked immunosorbent assay (ELISA). Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days post-injection 1 and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Due to Any Serotype Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>28 days post-injection 2 and up to 13 months post-injection 3</time_frame>
    <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Meeting World Health Organization (WHO) Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
    <description>Dengue hemorrhagic fever (DHF) cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria. (a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentration (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/ or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptomatic VCD Cases Meeting WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate in the Surveillance Expansion Period to the end of study (up to 72 months)</time_frame>
    <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant, usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 up to the end of study (up to 72 months)</time_frame>
    <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate in the Surveillance Expansion Period to end of the study (up to 72 months)</time_frame>
    <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
    <description>The severity of VCD cases was assessed by an Independent Data monitoring Committee (IDMC) based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by Glasgow Coma Scale (GCS) score 5) Liver impairment (AST &gt;1000 IU/L or prothrombin time [PT] International normalized ratio [INR] &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>From consent to participate in the Surveillance Expansion Period to the end of study (up to 72 months)</time_frame>
    <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:-1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Antibody Titers &gt;=10 1/Dil Against Each Dengue Virus Serotype Before and Following Injection (Inj.) With CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (Visit [V] 07) and 60 months (Visit [V] 12) post-injection 3</time_frame>
    <description>Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (parental strains) were measured by the plaque reduction neutralization test in a pre-defined subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</measure>
    <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (V 07) and 60 months (V 12) post-injection 3</time_frame>
    <description>Geometric mean titers for each of the 4 dengue virus serotypes (parental strains) were assessed using the plaque reduction neutralization test in a pre-defined subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Injection Site Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Within 7 days after each and any injection</time_frame>
    <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (9-11 years): Pain: incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-16 years): Pain: significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</measure>
    <time_frame>Within 14 days after each and any injection</time_frame>
    <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20869</enrollment>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>CYD Dengue Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were to receive a placebo vaccine at 0, 6, and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live, attenuated, dengue serotype 1, 2, 3, 4 virus</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>CYD Dengue Vaccine Group</arm_group_label>
    <other_name>CYD Dengue Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo: (NaCl) 0.9% solution</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 9 to 16 years on the day of inclusion and resident of the site zone

          -  Participant in good health, based on medical history and physical examination

          -  Assent form or informed consent form has been signed and dated by the participant
             (based on local regulations), and informed consent form has been signed and dated by
             the parent(s) or another legally acceptable representative (and by an independent
             witness if required by local regulations)

          -  Participant was able to attend all scheduled visits and comply with all trial
             procedures.

        Exclusion Criteria:

          -  Participant was pregnant, or lactating, or of childbearing potential (to be considered
             of non-childbearing potential, a female must be pre-menarche for at least 1 year,
             surgically sterile, or using an effective method of contraception or abstinence from
             at least 4 weeks prior to the first vaccination until at least 4 weeks after the last
             vaccination).

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Self-reported or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection

          -  Self-reported systemic hypersensitivity to any of the vaccine components, or history
             of a life-threatening reaction to the vaccine used in the trial or to a vaccine
             containing any of the same substances

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere
             with assessment of the immune response

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination

          -  Deprived of freedom by administrative or court order, or in an emergency setting, or
             hospitalized involuntarily

          -  Current alcohol abuse or drug addiction that may interfere with the participant's
             ability to comply with trial procedures

          -  Identified as a site employee of the Investigator or study center, with direct
             involvement in the proposed study or other studies under the direction of that
             Investigator or study center, as well as a family member (i.e., immediate, husband,
             wife and their children, adopted or natural) of the site employees or the
             Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430 270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitória</city>
        <state>ES</state>
        <zip>29040 09</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74675 020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campo Grande</city>
        <state>MS</state>
        <zip>79074 460</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <zip>59025 600</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguazul</city>
        <state>Casanare</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yopal</city>
        <state>Casanare</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girardot</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Acacias</city>
        <state>Meta</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Armenia</city>
        <state>Quindío</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calarcá</city>
        <state>Quindío</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tebaida</city>
        <state>Quindío</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montenegro</city>
        <state>Quindío</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tegucigalpa</city>
        <state>Municipalidad Del Distrito Central</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temixco</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Municipio De Cd. Mante</city>
        <state>Tamaulipas</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veracruz Puerto</city>
        <state>Veracruz</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tizimin</city>
        <state>Yucatán</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <state>Yucatán</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guayama</city>
        <zip>00784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Honduras</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.</citation>
    <PMID>25365753</PMID>
  </results_reference>
  <results_reference>
    <citation>Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.</citation>
    <PMID>26214039</PMID>
  </results_reference>
  <results_reference>
    <citation>Arredondo-García JL, Hadinegoro SR, Reynales H, Chua MN, Rivera Medina DM, Chotpitayasunondh T, Tran NH, Deseda CC, Wirawan DN, Cortés Supelano M, Frago C, Langevin E, Coronel D, Laot T, Perroud AP, Sanchez L, Bonaparte M, Limkittikul K, Chansinghakul D, Gailhardou S, Noriega F, Wartel TA, Bouckenooghe A, Zambrano B; CYD-TDV Dengue Vaccine Study Group. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018 Jul;24(7):755-763. doi: 10.1016/j.cmi.2018.01.018. Epub 2018 Feb 8.</citation>
    <PMID>29408333</PMID>
  </results_reference>
  <results_reference>
    <citation>L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, Villar L, Capeding MR, Ochiai RL; CYD14 Primary Study Group; CYD15 Primary Study Group. Symptomatic Dengue in Children in 10 Asian and Latin American Countries. N Engl J Med. 2016 Mar 24;374(12):1155-66. doi: 10.1056/NEJMoa1503877.</citation>
    <PMID>27007959</PMID>
  </results_reference>
  <results_reference>
    <citation>Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018 Jul 26;379(4):327-340. doi: 10.1056/NEJMoa1800820. Epub 2018 Jun 13.</citation>
    <PMID>29897841</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <results_first_submitted>September 25, 2016</results_first_submitted>
  <results_first_submitted_qc>March 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2019</results_first_posted>
  <disposition_first_submitted>January 11, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 11, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 12, 2016</disposition_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue Virus</keyword>
  <keyword>Dengue fever</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD dengue vaccine</keyword>
  <keyword>Flavivirus</keyword>
  <keyword>Dengue Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 08 June 2011 to 16 March 2012 at 5 clinical centers in Brazil, 9 in Colombia, 1 in Honduras, 5 in Mexico, and 2 in Puerto Rico.</recruitment_details>
      <pre_assignment_details>A total of 20869 participants were enrolled and randomized in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccination Phase (Up to 25 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13920"/>
                <participants group_id="P2" count="6949"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13281"/>
                <participants group_id="P2" count="6640"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="639"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Surveillance Expansion Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13281"/>
                <participants group_id="P2" count="6640"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10932"/>
                <participants group_id="P2" count="5387"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2349"/>
                <participants group_id="P2" count="1253"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1870"/>
                <participants group_id="P2" count="986"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13920"/>
            <count group_id="B2" value="6949"/>
            <count group_id="B3" value="20869"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13920"/>
                    <measurement group_id="B2" value="6949"/>
                    <measurement group_id="B3" value="20869"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.5" spread="2.14"/>
                    <measurement group_id="B2" value="12.5" spread="2.13"/>
                    <measurement group_id="B3" value="12.5" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7048"/>
                    <measurement group_id="B2" value="3532"/>
                    <measurement group_id="B3" value="10580"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6872"/>
                    <measurement group_id="B2" value="3417"/>
                    <measurement group_id="B3" value="10289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6497"/>
                    <measurement group_id="B2" value="3246"/>
                    <measurement group_id="B3" value="9743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2370"/>
                    <measurement group_id="B2" value="1178"/>
                    <measurement group_id="B3" value="3548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2312"/>
                    <measurement group_id="B2" value="1152"/>
                    <measurement group_id="B3" value="3464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Honduras</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1866"/>
                    <measurement group_id="B2" value="933"/>
                    <measurement group_id="B3" value="2799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="875"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="1315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction (RT-PCR) and/or dengue non-structural (NS) protein 1 antigen enzyme-linked immunosorbent assay (ELISA). Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
        <time_frame>28 days and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Per-Protocol Analysis Set for Efficacy, defined as participants who had no protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue reverse transcriptase polymerase chain reaction (RT-PCR) and/or dengue non-structural (NS) protein 1 antigen enzyme-linked immunosorbent assay (ELISA). Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Per-Protocol Analysis Set for Efficacy, defined as participants who had no protocol deviations.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12574"/>
                <count group_id="O2" value="6261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% confidence interval (CI) of the vaccine efficacy (expressed in %). The CI was calculated using the exact method conditional on the total number of cases in both groups (exact method by Breslow &amp; Day). The vaccine efficacy of the CYD dengue vaccine was considered significant if the lower bound of its 95% CI was greater than 25%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>60.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.0</ci_lower_limit>
            <ci_upper_limit>68.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
        <time_frame>Day 0 up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included all participants who received at least 1 injection.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype During the Active Phase Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included all participants who received at least 1 injection.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13914"/>
                <count group_id="O2" value="6940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>64.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.7</ci_lower_limit>
            <ci_upper_limit>69.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
        <time_frame>28 days post-injection 1 and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included participants who received at least 1 dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype Occurring 28 Days Post-dose 1 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Full Analysis Set for Efficacy, which included participants who received at least 1 dose of study vaccine.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13914"/>
                <count group_id="O2" value="6940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>64.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.7</ci_lower_limit>
            <ci_upper_limit>69.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Due to Any Serotype Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
        <time_frame>28 days post-injection 2 and up to 13 months post-injection 3</time_frame>
        <population>Number of symptomatic VCD cases were assessed in the Other Efficacy Analysis Set, which included participants who received at least 2 doses of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Due to Any Serotype Post-dose 2 Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Symptomatic VCD cases were defined as occurrence of acute febrile illness (temperature &gt;= 38°C on at least 2 consecutive days) and confirmation of dengue virus infection by dengue RT-PCR and/or dengue NS 1 ELISA. Vaccine efficacy was defined as 1 minus the ratio of density incidence due to any serotype after at least 1 dose in the CYD Dengue Vaccine Group over the density incidence of the Placebo Group.</description>
          <population>Number of symptomatic VCD cases were assessed in the Other Efficacy Analysis Set, which included participants who received at least 2 doses of study vaccine.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13506"/>
                <count group_id="O2" value="6765"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical methodology was based on the use of the two-sided 95% CI of the vaccine efficacy (expressed in %) calculated using the exact method conditional on the total number of cases in both groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>61.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.7</ci_lower_limit>
            <ci_upper_limit>68.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Meeting World Health Organization (WHO) Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Dengue hemorrhagic fever (DHF) cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria. (a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentration (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/ or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
        <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
        <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Safety Analysis Set, which included all participants who received at least one dose of study vaccine. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Meeting World Health Organization (WHO) Criteria Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Dengue hemorrhagic fever (DHF) cases were defined as number of participants with at least one symptomatic VCD episode meeting the 1997 WHO criteria. (a) Fever: acute onset, high (&gt;= 38°C) and continuous, lasting 2 to 7 days and (b) any of the pre-listed hemorrhagic manifestations and laboratory findings of thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hemoconcentration (hematocrit increased by 20% or more) or pleural effusion (seen on CXR) and/or ascites and/ or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish a clinical diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhage.</description>
          <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Safety Analysis Set, which included all participants who received at least one dose of study vaccine. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12809"/>
                <count group_id="O2" value="6380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Due to Any of the 4 Serotypes: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Symptomatic VCD Cases Meeting WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant, usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
        <time_frame>From consent to participate in the Surveillance Expansion Period to the end of study (up to 72 months)</time_frame>
        <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Full Analysis Set for Surveillance Expansion Period, which included all participants who received at least 1 injection and accepted to be included in the Surveillance Expansion Period.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptomatic VCD Cases Meeting WHO Criteria During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The 1997 WHO criteria are: a) Fever: acute onset, high (&gt;= 38°C) and continuous, for 2 to 7 days and (b) any of the following: thrombocytopenia (platelet &lt;=100 x 109/L) and plasma leakage as shown by hematocrit increased by 20% or more or pleural effusion and/or ascites and/or hypoalbuminemia. The first two clinical criteria plus thrombocytopenia and signs of plasma leakage are enough to establish diagnosis of DHF. DHF was graded as follows: Grade I: Fever accompanied by non-specific constitutional symptoms; the only hemorrhagic manifestation is a positive tourniquet test; Grade II: Spontaneous bleeding in addition to the manifestations of Grade I participant, usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of cold clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse.</description>
          <population>Number of WHO dengue hemorrhagic fever cases were assessed in the Full Analysis Set for Surveillance Expansion Period, which included all participants who received at least 1 injection and accepted to be included in the Surveillance Expansion Period.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11063"/>
                <count group_id="O2" value="5430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Due to Any of the 4 Serotypes: Any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Due to Any of the 4 Serotypes: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
        <time_frame>Day 0 up to the end of study (up to 72 months)</time_frame>
        <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalized VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
          <population>Number of hospitalized dengue hemorrhagic fever cases were assessed in the Safety Analysis Set. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12809"/>
                <count group_id="O2" value="6380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
        <time_frame>From consent to participate in the Surveillance Expansion Period to end of the study (up to 72 months)</time_frame>
        <population>Analysis was performed in the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months and were followed up to 60 months after last vaccination (or a total duration of up to 72 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalized VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Hospitalized VCD cases were defined as VCD confirmed by dengue RT-PCR and/or dengue NS 1 ELISA in participants with acute febrile illness (temperature &gt;=38°C on at least 2 consecutive days) requiring hospitalization.</description>
          <population>Analysis was performed in the Safety Analysis Set.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13915"/>
                <count group_id="O2" value="6939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The severity of VCD cases was assessed by an Independent Data monitoring Committee (IDMC) based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by Glasgow Coma Scale (GCS) score 5) Liver impairment (AST &gt;1000 IU/L or prothrombin time [PT] International normalized ratio [INR] &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
        <time_frame>Day 0 to the end of study (up to 72 months)</time_frame>
        <population>Number of clinically severe VCD cases were assessed in the Safety Analysis Set. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Severe VCD Cases Throughout the Trial Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The severity of VCD cases was assessed by an Independent Data monitoring Committee (IDMC) based on a medical review of cases and any of the following criteria:1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by Glasgow Coma Scale (GCS) score 5) Liver impairment (AST &gt;1000 IU/L or prothrombin time [PT] International normalized ratio [INR] &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
          <population>Number of clinically severe VCD cases were assessed in the Safety Analysis Set. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12809"/>
                <count group_id="O2" value="6380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:-1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
        <time_frame>From consent to participate in the Surveillance Expansion Period to the end of study (up to 72 months)</time_frame>
        <population>Number of clinically severe VCD cases were assessed in the Full Analysis Set for Surveillance Expansion Period. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Severe VCD Cases During the Surveillance Expansion Period Due to Any Serotype Following Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>The severity of VCD cases was assessed by an IDMC based on a medical review of cases and any of the following criteria:-1) Platelet count &lt;=100000 /μl and bleeding (tourniquet, petechiae or any bleeding) plus plasma leakage 2) Shock (pulse pressure &lt;= 20 mmHg in a child, or hypotension [&lt;= 90 mmHg] with tachycardia, weak pulse and poor perfusion) 3) Bleeding requiring blood transfusion 4) Encephalopathy i.e. Unconsciousness or poor conscious state or fitting not attributable to simple febrile convulsion or focal neurological signs. Poor conscious state or unconsciousness must be supported by GCS score 5) Liver impairment (AST &gt;1000 IU/L or PT INR &gt;1.5) excluding other causes of viral hepatitis 6) Impaired kidney function (serum creatinine &gt;= 1.5 mg/dL) 7) Myocarditis, pericarditis or clinical heart failure supported by CXR, echocardiography, ECG or cardiac enzymes.</description>
          <population>Number of clinically severe VCD cases were assessed in the Full Analysis Set for Surveillance Expansion Period. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11061"/>
                <count group_id="O2" value="5431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Antibody Titers &gt;=10 1/Dil Against Each Dengue Virus Serotype Before and Following Injection (Inj.) With CYD Dengue Vaccine or Placebo</title>
        <description>Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (parental strains) were measured by the plaque reduction neutralization test in a pre-defined subset of participants.</description>
        <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (Visit [V] 07) and 60 months (Visit [V] 12) post-injection 3</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in Full Analysis Set for Immunogenicity(FASI),which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose.Here, ‘number analyzed’=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subset of participants who received at least one dose of CYD Dengue vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subset of participants who received at least one dose of placebo vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Antibody Titers &gt;=10 1/Dil Against Each Dengue Virus Serotype Before and Following Injection (Inj.) With CYD Dengue Vaccine or Placebo</title>
          <description>Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (parental strains) were measured by the plaque reduction neutralization test in a pre-defined subset of participants.</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in Full Analysis Set for Immunogenicity(FASI),which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose.Here, ‘number analyzed’=participants with available data for each specified category.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1: Pre-Inj.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8"/>
                    <measurement group_id="O2" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1: Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1: Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; 1 year Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1261"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6"/>
                    <measurement group_id="O2" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; 5 year Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                    <measurement group_id="O2" value="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1299"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1"/>
                    <measurement group_id="O2" value="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; 1 year Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1264"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; 5 year Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5"/>
                    <measurement group_id="O2" value="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1300"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; 1 year Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1265"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7"/>
                    <measurement group_id="O2" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; 5 year Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4"/>
                    <measurement group_id="O2" value="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1295"/>
                    <count group_id="O2" value="637"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9"/>
                    <measurement group_id="O2" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post-Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; 1 year Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1265"/>
                    <count group_id="O2" value="625"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; 5 year Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</title>
        <description>Geometric mean titers for each of the 4 dengue virus serotypes (parental strains) were assessed using the plaque reduction neutralization test in a pre-defined subset of participants.</description>
        <time_frame>Pre-injection 1, 28 days post Injections 2 and 3, 13 months (V 07) and 60 months (V 12) post-injection 3</time_frame>
        <population>Antibody titers against each dengue virus serotype strain were assessed in FASI, which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here,‘number analyzed’ = participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Subset of participants who received at least one dose of CYD Dengue vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subset of participants who received at least one dose of the placebo vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Before and Following Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo</title>
          <description>Geometric mean titers for each of the 4 dengue virus serotypes (parental strains) were assessed using the plaque reduction neutralization test in a pre-defined subset of participants.</description>
          <population>Antibody titers against each dengue virus serotype strain were assessed in FASI, which included a subset of participants who received at least one dose of vaccine and had a blood sample drawn and result available after the dose. Here,‘number analyzed’ = participants with available data for each specified category.</population>
          <units>Titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1301"/>
                <count group_id="O2" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dengue virus Serotype 1; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="641"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="112" upper_limit="145"/>
                    <measurement group_id="O2" value="119" lower_limit="98.7" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="638"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458" lower_limit="406" upper_limit="517"/>
                    <measurement group_id="O2" value="128" lower_limit="106" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395" lower_limit="353" upper_limit="441"/>
                    <measurement group_id="O2" value="121" lower_limit="101" upper_limit="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1261"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" lower_limit="234" upper_limit="302"/>
                    <measurement group_id="O2" value="146" lower_limit="121" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 1; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" lower_limit="252" upper_limit="321"/>
                    <measurement group_id="O2" value="210" lower_limit="172" upper_limit="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1299"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138" lower_limit="123" upper_limit="156"/>
                    <measurement group_id="O2" value="115" lower_limit="97.2" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622" lower_limit="566" upper_limit="684"/>
                    <measurement group_id="O2" value="124" lower_limit="104" upper_limit="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574" lower_limit="528" upper_limit="624"/>
                    <measurement group_id="O2" value="129" lower_limit="109" upper_limit="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 1 Post-Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1264"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371" lower_limit="336" upper_limit="409"/>
                    <measurement group_id="O2" value="145" lower_limit="122" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 2; Year 5 Post-Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297" lower_limit="269" upper_limit="328"/>
                    <measurement group_id="O2" value="201" lower_limit="168" upper_limit="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Pre-Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1300"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="108" upper_limit="136"/>
                    <measurement group_id="O2" value="114" lower_limit="95.9" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556" lower_limit="506" upper_limit="610"/>
                    <measurement group_id="O2" value="117" lower_limit="98.3" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508" lower_limit="465" upper_limit="555"/>
                    <measurement group_id="O2" value="124" lower_limit="105" upper_limit="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1265"/>
                    <count group_id="O2" value="629"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292" lower_limit="263" upper_limit="325"/>
                    <measurement group_id="O2" value="137" lower_limit="114" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 3; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346" lower_limit="313" upper_limit="383"/>
                    <measurement group_id="O2" value="224" lower_limit="185" upper_limit="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Pre Inj. 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="39.6" upper_limit="48.0"/>
                    <measurement group_id="O2" value="39.0" lower_limit="33.9" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Inj. 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1295"/>
                    <count group_id="O2" value="637"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261" lower_limit="242" upper_limit="281"/>
                    <measurement group_id="O2" value="40.9" lower_limit="35.5" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Post Inj. 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1291"/>
                    <count group_id="O2" value="640"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="226" upper_limit="258"/>
                    <measurement group_id="O2" value="44.3" lower_limit="38.6" upper_limit="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 1 Post Inj. 3 (V 07)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1265"/>
                    <count group_id="O2" value="625"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="161" upper_limit="188"/>
                    <measurement group_id="O2" value="51.5" lower_limit="44.3" upper_limit="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue virus Serotype 4; Year 5 Post Inj. 3 (V 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1038"/>
                    <count group_id="O2" value="508"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="134" upper_limit="156"/>
                    <measurement group_id="O2" value="73.6" lower_limit="63.4" upper_limit="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Injection Site Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (9-11 years): Pain: incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-16 years): Pain: significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
        <time_frame>Within 7 days after each and any injection</time_frame>
        <population>Solicited injection site reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine and who were evaluated for reactogenicity. Here, ‘number analyzed’ = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Solicited injection site reactions: Pain, Erythema, and Swelling. Grade 3 reactions (9-11 years): Pain: incapacitating, unable to perform usual activities; Erythema and Swelling, &gt;= 50 mm. Grade 3 Solicited injection site reactions (12-16 years): Pain: significant, prevents daily activity; Erythema and Swelling, &gt;100 mm.</description>
          <population>Solicited injection site reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine and who were evaluated for reactogenicity. Here, ‘number analyzed’ = participants with available data for specified category.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site Pain (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="658"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1326"/>
                    <count group_id="O2" value="656"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1296"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Pain (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1279"/>
                    <count group_id="O2" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Pain (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1279"/>
                    <count group_id="O2" value="630"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Erythema (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1278"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Erythema (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1278"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site Swelling (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1279"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site Swelling (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1279"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Systemic Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</title>
        <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
        <time_frame>Within 14 days after each and any injection</time_frame>
        <population>Solicited systemic reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine and who were evaluated for reactogenicity. Here, 'number analyzed' = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>CYD Dengue Vaccine Group</title>
            <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received 3 doses of placebo matched to vaccine; one each at 0, 6, and 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions Following Any and Each Injection With Either CYD Dengue Vaccine or a Placebo</title>
          <description>Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 reactions: Fever: &gt;= 39°C; Headache, Malaise, Myalgia, and Asthenia: significant, prevents daily activity.</description>
          <population>Solicited systemic reactions were assessed in a subset of the Safety Analysis Set, which included all participants who received at least one dose of study vaccine and who were evaluated for reactogenicity. Here, 'number analyzed' = participants with available data for specified category.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1333"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1318"/>
                    <count group_id="O2" value="654"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="659"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727"/>
                    <measurement group_id="O2" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="659"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="659"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="576"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post any injection)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="659"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496"/>
                    <measurement group_id="O2" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1264"/>
                    <count group_id="O2" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1264"/>
                    <count group_id="O2" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1324"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528"/>
                    <measurement group_id="O2" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1324"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1323"/>
                    <count group_id="O2" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1228"/>
                    <count group_id="O2" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1228"/>
                    <count group_id="O2" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1297"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1215"/>
                    <count group_id="O2" value="597"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1215"/>
                    <count group_id="O2" value="597"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Asthenia (Post-injection 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1277"/>
                    <count group_id="O2" value="631"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited adverse event (AE) data were collected from Day 0 (post-vaccination) up to 28 days after each vaccination. Solicited Reaction (SR) data were collected within 7 and 14 days after vaccination. Serious adverse event (SAE) data were collected throughout the study (up to 72 months).</time_frame>
      <desc>Analysis were performed on Safety Analysis Set. A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>CYD Dengue Vaccine Group</title>
          <description>Participants received 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participants received 3 doses of placebo vaccine; one each at 0, 6, and 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="13915"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1765" subjects_at_risk="13915"/>
                <counts group_id="E2" subjects_affected="911" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anaemia Of Pregnancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Aplastic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lymphoid Tissue Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Atrial Septal Defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hereditary Spherocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sickle Cell Trait</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hypothalamo-Pituitary Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratoconus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="13915"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intestinal Functional Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Malocclusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia, Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Varices Oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vomiting In Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Device Intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Soft Tissue Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13915"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholestasis Of Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gallbladder Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy To Arthropod Sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Antiphospholipid Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Infected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abscess Neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abscess Of Salivary Gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abscess Oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Amniotic Cavity Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Amoebic Dysentery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anogenital Warts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="261" subjects_affected="261" subjects_at_risk="13915"/>
                <counts group_id="E2" events="138" subjects_affected="138" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Asymptomatic Hiv Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bartholin's Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="13915"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chikungunya Virus Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chronic Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cutaneous Anthrax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" events="104" subjects_affected="101" subjects_at_risk="13915"/>
                <counts group_id="E2" events="94" subjects_affected="94" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Endometritis Decidual</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Enterocolitis Infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>External Ear Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Eye Infection Toxoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Flavivirus Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="13915"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bacterial Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Genital Infection Female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Genitourinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Granuloma Inguinale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>H1n1 Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hiv Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hiv Infection Cdc Category A3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Helminthic Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Ophthalmic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Infected Bites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Infectious Mononucleosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Infective Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mastitis Postpartum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mononucleosis Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mycoplasma Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteomyelitis Chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pancreatitis Mumps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Panencephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Parasitic Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory Disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Perineal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="13915"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pneumonia Mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Postpartum Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Scarlet Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Secondary Syphilis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tonsillitis Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="127" subjects_affected="118" subjects_at_risk="13915"/>
                <counts group_id="E2" events="69" subjects_affected="59" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Viral Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="13915"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Visceral Leishmaniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vulval Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Accident At Home</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Accident At Work</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acetabulum Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Adverse Event Following Immunisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Avulsion Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Burns Second Degree</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Burns Third Degree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chemical Poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chest Injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Endotracheal Intubation Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Epiphyseal Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Eye Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Eye Penetration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Face Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="13915"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="13915"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Foreign Body In Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Genital Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="13915"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Limb Crushing Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Limb Traumatic Amputation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Muscle Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nerve Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Open Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Perineal Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pneumothorax Traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Poisoning Deliberate</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="13915"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Procedural Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="109" subjects_affected="108" subjects_at_risk="13915"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Soft Tissue Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Spinal Cord Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Spinal Cord Injury Cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sports Injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Stab Wound</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tendon Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Testicular Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ulnar Nerve Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vascular Access Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Type 1 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Epiphysiolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Juvenile Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Knee Deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Rheumatic Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Systemic Lupus Erythematosus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Hydatidiform Mole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Benign Ovarian Tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Benign Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bone Giant Cell Tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bone Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Chronic Myeloid Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Desmoid Tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Fibroadenoma Of Breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemangioma Of Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hodgkin's Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteochondroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteosarcoma Metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Osteosarcoma Recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovarian Germ Cell Teratoma Benign</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pituitary Tumour Benign</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Disseminated Encephalomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Arachnoid Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Atonic Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cerebellar Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Complicated Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="13915"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="86" subjects_affected="26" subjects_at_risk="13915"/>
                <counts group_id="E2" events="27" subjects_affected="8" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Cerebral Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hypertensive Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Idiopathic Generalised Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Migraine With Aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Migraine Without Aura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Status Migrainosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal Product Of Conception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="13915"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Complete</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Complicated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="13915"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Incomplete Complicated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Missed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Of Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="51" subjects_affected="48" subjects_at_risk="13915"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Complete</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Complicated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Incomplete</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Incomplete Complicated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Threatened</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Amniorrhexis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Antepartum Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Blighted Ovum</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cephalo-Pelvic Disproportion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cervical Incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Complication Of Delivery</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Failed Induction Of Labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>False Labour</sub_title>
                <counts group_id="E1" events="45" subjects_affected="39" subjects_at_risk="13915"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Foetal Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gestational Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hellp Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>High Risk Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hyperemesis Gravidarum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intra-Uterine Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intrapartum Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Placental Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Postpartum Haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pre-Eclampsia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="13915"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Premature Baby</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Premature Delivery</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Premature Labour</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="13915"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Premature Rupture Of Membranes</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Premature Separation Of Placenta</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Prolonged Labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Puerperal Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Retained Placenta Or Membranes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Retained Products Of Conception</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ruptured Ectopic Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Threatened Labour</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Stress Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Adjustment Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anorexia Nervosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bipolar I Disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Conduct Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Conversion Disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="13915"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Depression Suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dissociative Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Drug Abuse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Drug Dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intentional Drug Misuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intentional Self-Injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Intermittent Explosive Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Obsessive Rumination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Schizophrenia, Undifferentiated Type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Somatoform Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Substance Abuse</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="13915"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="13915"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Calculus Urethral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Lupus Nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nephritic Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Post Streptococcal Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Urogenital Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Breast Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Coital Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haematocolpos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haematosalpinx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Ruptured</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovarian Torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Ovulation Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Polycystic Ovaries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Retrograde Menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Testicular Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Testicular Torsion</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Uterine Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Vulval Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Adenoidal Hypertrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Alveolitis Allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="13915"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="13915"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Bronchial Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Nasal Turbinate Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pulmonary Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Status Asthmaticus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tonsillar Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Tonsillar Hypertrophy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Erythema Nodosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Hypertrophic Scar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Mechanical Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Skin Fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Subcutaneous Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical Assault</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Sexual Abuse</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13915"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Substance Use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Victim Of Crime</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Victim Of Homicide</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Victim Of Sexual Abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion Induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Abortion Induced Complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Caesarean Section</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Obesity Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Scoliosis Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13915"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
              <event>
                <sub_title>Secondary Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13915"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6939"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1038" subjects_at_risk="1333"/>
                <counts group_id="E2" subjects_affected="515" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="771" subjects_affected="500" subjects_at_risk="1333"/>
                <counts group_id="E2" events="366" subjects_affected="253" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="99" subjects_affected="83" subjects_at_risk="1333"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="1056" subjects_affected="650" subjects_at_risk="1333"/>
                <counts group_id="E2" events="384" subjects_affected="270" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="92" subjects_affected="77" subjects_at_risk="1333"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="853" subjects_affected="539" subjects_at_risk="1333"/>
                <counts group_id="E2" events="383" subjects_affected="264" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="270" subjects_affected="238" subjects_at_risk="1333"/>
                <counts group_id="E2" events="142" subjects_affected="127" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="80" subjects_affected="76" subjects_at_risk="1333"/>
                <counts group_id="E2" events="40" subjects_affected="37" subjects_at_risk="664"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="163" subjects_affected="150" subjects_at_risk="1333"/>
                <counts group_id="E2" events="70" subjects_affected="60" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="921" subjects_affected="578" subjects_at_risk="1333"/>
                <counts group_id="E2" events="400" subjects_affected="267" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1385" subjects_affected="753" subjects_at_risk="1333"/>
                <counts group_id="E2" events="652" subjects_affected="388" subjects_at_risk="664"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

